Pharvaris (PHVS) Earnings Date & Reports

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

PHVS is expected to report earnings to rise 21.68% to -71 cents per share on November 18

Q3'26

Est.

$-0.72

Q1'26

Beat

by $0.12

Q4'25

Missed

by $0.10

Q3'25

Beat

by $0.08

Q2'25

Missed

by $0.06

The last earnings report on May 12 showed earnings per share of -58 cents, beating the estimate of -70 cents. With 900.21K shares outstanding, the current market capitalization sits at 2.67B.

View a ticker or compare two or three

PHVS

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for PHVS